Skip to content
drillr.ai
Sign up

KALA

KALA BIO, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.51
−9.57%
Ask drillr
Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$9.81M
RSI (14)
26.6
MomentumView details →
1D Return
−9.57%
YTD Return
−98.17%
SummaryUpdated Jun 1, 2026

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is a biopharmaceutical company founded in 2009 and headquartered in Watertown, Massachusetts. The company was originally incorporated as Hanes Newco, Inc. before changing its name in December 2009 and went public in July 2017. Kala has undergone significant strategic transformation in recent years, transitioning from a commercial-stage company with marketed eye care products to a research-focused organization developing novel therapies for ocular diseases using proprietary drug delivery technologies.

Ask drillr about KALA BIO, Inc. →

Similar companies

Aprea Therapeutics, Inc.APRECytoMed Therapeutics LimitedGDTCTevogen Bio Holdings Inc.TVGNWSenti Biosciences, Inc.SNTIenGene Holdings Inc. WarrantsENGNWVistaGen Therapeutics, Inc.VTGN
Latest newsMore news →
KALA BIO, Inc. received a notice from NASDAQ on August 27, 2026, stating that it is not in compliance with Listing Rule 5550(a)(2) regarding the minimum bid price requirement, and the company has requested a hearing before a NASDAQ panel.8d ago